Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 1
1997 1
1998 1
1999 4
2000 3
2001 2
2002 1
2003 2
2004 3
2005 3
2006 3
2007 9
2008 9
2009 8
2010 5
2011 9
2012 13
2013 8
2014 18
2015 19
2016 17
2017 18
2018 16
2019 17
2020 22
2021 14
2022 15
2023 8
2024 12
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J. Portuguese AJ, et al. Among authors: gopal ak. Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010. Online ahead of print. Haematologica. 2025. PMID: 40079097 Free article.
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity …
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell th …
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.
Gopal AK, Armand P, Neelapu SS, Bartlett NL, Spurgeon SE, Kuruvilla J, Savage KJ, Leonard JP, Gelb AB, Ahmed N, Dong S, Bathena SP, Suryawanshi R, Wu QJ, Wang S, Gladstone DE. Gopal AK, et al. Blood Adv. 2025 Mar 3:bloodadvances.2024015086. doi: 10.1182/bloodadvances.2024015086. Online ahead of print. Blood Adv. 2025. PMID: 40030000
Despite high response rates, anti-PD-1 therapy monotherapy eventually fails in most patients with relapsed or refractory Hodgkin Lymphoma (HL) and is generally ineffective in most other B-cell malignancies. The lymphocyte activation gene 3 (LAG-3) cell-surface receptor rep …
Despite high response rates, anti-PD-1 therapy monotherapy eventually fails in most patients with relapsed or refractory Hodgkin Lymphoma …
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Samples L, et al. Among authors: gopal ak. Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831. Online ahead of print. Blood. 2025. PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. ...
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory dise …
Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024.
Olivieri DJ, Gopal AK, Uldrick TS, Menon MP. Olivieri DJ, et al. Among authors: gopal ak. Cancer Invest. 2025 Feb;43(2):141-148. doi: 10.1080/07357907.2025.2462568. Epub 2025 Feb 8. Cancer Invest. 2025. PMID: 39921375
BACKGROUND: Human immunodeficiency virus is associated with the development of various aggressive non-Hodgkin B-cell lymphomas (NHL). Despite this, people living with HIV (PLWH) are often excluded from clinical trials. ...METHODS: We identified all US-based clinical trials …
BACKGROUND: Human immunodeficiency virus is associated with the development of various aggressive non-Hodgkin B-cell lymphomas (NHL). …
A phase 2 study of frontline pembrolizumab in follicular lymphoma.
Ho C, Zhu S, Gooley T, Gujral TS, Lynch RC, Poh C, Shadman M, Smith SD, Tseng Y, Gopal AK. Ho C, et al. Among authors: gopal ak. EJHaem. 2024 Oct 10;5(6):1173-1181. doi: 10.1002/jha2.1029. eCollection 2024 Dec. EJHaem. 2024. PMID: 39691260 Free PMC article.
Thus, we developed a phase 2 study to evaluate the efficacy of pembrolizumab as the initial treatment for indolent B-cell lymphoma. METHODS: Adults with FL or marginal zone lymphoma and an indication for treatment were eligible. ...RESULTS: Nine patients with FL wer …
Thus, we developed a phase 2 study to evaluate the efficacy of pembrolizumab as the initial treatment for indolent B-cell lymphoma. M …
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: gopal ak. Blood Adv. 2025 Feb 11;9(3):606-616. doi: 10.1182/bloodadvances.2024014455. Blood Adv. 2025. PMID: 39626349 Free PMC article.
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience.
Huang IJ, Baek GT, Cohen J, Khajaviyan S, Louie S, Samples L, Smith SD, Till BG, Warren EH, Gopal AK, Poh C, Lynch RC, Ujjani CS, Shadman M. Huang IJ, et al. Among authors: gopal ak. JCO Oncol Pract. 2024 Nov 18:OP2400416. doi: 10.1200/OP.24.00416. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39556786
PURPOSE: Venetoclax is the standard of care for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) but requires intensive monitoring for optimal safety. Clinical relevance of intensive monitoring in practice is unknown, especially for patients with low or …
PURPOSE: Venetoclax is the standard of care for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) but requires inte …
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Shadman M, et al. Among authors: gopal ak. Blood Cancer J. 2024 Jul 8;14(1):108. doi: 10.1038/s41408-024-01084-w. Blood Cancer J. 2024. PMID: 38977682 Free PMC article.
Mitigating time toxicity in lymphoma and multiple myeloma.
Di M, Su CT, Cowan AJ, Gopal AK, Banerjee R. Di M, et al. Among authors: gopal ak. Leuk Lymphoma. 2024 Oct;65(10):1418-1429. doi: 10.1080/10428194.2024.2352086. Epub 2024 May 15. Leuk Lymphoma. 2024. PMID: 38749027 Review.
In this review, we examine several manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma and discuss their impact on decision-making with patients. ...Throughout the review, we highlight strategies to lower the time toxicity of therapies in lympho …
In this review, we examine several manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma and discuss their imp …
230 results